KRAS and non-small cell lung carcinoma: Another phase I study focuses on the safety and tolerability of pembrolizumab infusion in combination with mRNA-5671/V941 (a KRAS vaccine) in patients with KRAS mutant advanced or metastatic NSCLC (NCT03948763).